Objective: Some lipid-lowering agents, for example, nicotinic acid and fibrates, decrease an individual's ability to metabolise fat during exercise. However, it is unclear whether statins affect fat metabolism during exercise in patients. This study investigated whether fatty acid oxidation is impaired in a dyslipidemic population, while walking at a moderate intensity. Methods: Patients (n=16), walked for 45 minutes on a treadmill at 50% of their estimated V O2max, in the absence and presence of their prescribed statin. Fat metabolism was investigated by examining respiratory data, and circulating plasma glycerol and free fatty acids. Results: Analysis of respiratory data indicated a progressive increase in fat oxidation over time, along with a decrease in carbohydrate oxidation, for all patients during exercise, in both the absence and presence of a statin (P≤0.05). The increase in the percent of energy derived from fat was further supported by the observation of a significantly progressive increase in circulating glycerol and free fatty acids during the exercise period. However no significant difference in the extent of change was observed when comparing the respiratory and biochemical response to physical activity in the absence and presence of the prescribed statin. Conclusions: There is no evidence of a negative impact of statins on the ability to metabolise fat as a fuel for moderate-intensity aerobic exercise. Given the importance of physical activity, this result encourages patients to participate in regular exercise without concern of premature fatigue. supported by the observation of a significantly progressive increase in circulating glycerol and free fatty 36 acids during the exercise period. However no significant difference in the extent of change was observed 37 when comparing the respiratory and biochemical response to physical activity in the absence and 38 presence of the prescribed statin. 39
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Introduction 47 Lipid-lowering drugs are amongst the most commonly subsidized prescribed drugs world-wide, 48
including Europe and the United States (USA). In 2016, atorvastatin and simvastatin were ranked in 49 positions 1 and 7 in the USA [1] . In the same year, in Australia, atorvastatin and rosuvastatin were in 50 positions 1 and 3, with the number of Australians per thousand taking the drug daily being 53 for 51 atorvastatin and 34 for rosuvastatin [2] . 52
Physiologically, these drugs inhibit liver enzyme HMG-CoA reductase, blocking cholesterol 53 synthesis. They are recognized as effective in the secondary prevention of cardiovascular disease and 54 all-cause mortality [3] . However, it is now well established that a healthy diet and regular physical 55 activity are valuable contributors to maintaining healthy blood lipids, with exercise improving 56 cardiovascular fitness; reducing all-cause mortality and the risk of coronary heart and cardiovascular 57 disease, stroke, type 2 diabetes mellitus (T2DM), and obesity. A recent meta-analysis highlighted that 58 physical activity alone is potentially as effective as many drug interventions on mortality outcomes in 59 coronary heart disease, stroke, heart failure, and prediabetes [4] . Despite this, there exists a bias against 60 exercise intervention with a subsequent progression towards lowering the threshold for pharmaceutical 61 treatment, and an increased likelihood that individuals embarking on an exercise regime are already 62 taking a cholesterol-lowering agent as a secondary or even primary prevention against cardiovascular 63 risk. To maximize the benefit of pharmaceutical intervention and exercise, it is important therefore, to 64 understand the effect of these drugs on the body's response to exercise. 65
Lipid stores, critical for fueling prolonged exercise, exist as triglycerides in adipose tissue and 66 muscle, and also as circulating triglycerides. Hormone-sensitive lipase (HSL), an intracellular enzyme in 67 adipose tissue, and lipoprotein lipase (LPL), an enzyme which hydrolyzes the triglyceride core of 68 circulating chylomicrons, both liberate free fatty acids (FFA) for use by exercising muscle. Any drugs 69 acting at these sites, could potentially alter FFA availability, resulting in increasing dependence on 70 E x e r c i s e M e d i c i n e muscle glycogen stores and earlier fatigue [5] . Studies in healthy volunteers undertaking exercise have 71 found that the lipid-lowering drugs, acipimox, and fibrates such as bezafibrate and gemfibrozil, have a 72 negative impact on fat oxidation [5, 6] . This increases demand for carbohydrate (CHO), and is thought to 73 contribute to a reduction in exercise tolerance. However, no negative impact of simvastatin, fluvastatin 74 or atorvastatin has been observed in healthy exercising participants [5, 6, 7] . 75
In contrast, the impact of statins on fat metabolism in patient cohorts is less clear. The available 76 research in patients undergoing exercise has produced conflicting results, with studies confounded by 77 the co-administration of a kaleidoscope of other cholesterol-lowering agents, or with β-blockers, which 78 inhibit the release of FFA from adipose tissue and complicate the interpretation of the data [8, 9] . One 79 study in patients has reported reduced fat oxidation with atorvastatin, during lower-intensity exercise 80
[10]. Patients have also self-reported increased fatigue with exertion after taking simvastatin for a period 81 of 6 months [11] . In contrast, other studies have reported no negative impact of statins on fat metabolism 82 [12, 13] . 83
Given the importance of exercise in these patients, and the limited and conflicting data on the 84 interaction between cholesterol-lowering agents and physical activity, the current study investigated in a 85 dyslipidemic population, whether statins impair fatty acid oxidation during exercise of moderate-86 intensity. This study is unique as it appears to be the first longitudinal investigation of fat metabolism in 87 both the absence and presence of a statin during exercise, within the same group of patients. ) and respiratory exchange ratio (RER) (V CO 2 /V O 2 ) were measured using a 127 metabolic cart (ParvoMedics TrueMax 2400). HR was monitored via an electrocardiogram (ECG) and a 128 HR monitor. Participants chose a comfortable walking speed at 0% gradient. With the speed constant, 129 exercise intensity was increased a further two times, by increasing the gradient of the treadmill belt 130 every 3-5 min after a stable exercise HR was recorded. The predicted maximum oxygen consumption 131 was calculated by plotting exercise HR against oxygen consumption, with a line of best fit extrapolated 132 to the point of each participant's maximal predicted HR [15] . The relative perceived exertion (RPE) [15] Body composition data revealed that participants were on average overweight, had an increased disease 204 risk relative to weight and waist circumference, and a moderate disease risk based on waist-hip ratio [15] . 205
Regarding physical activity, participants reported an average occupational activity intensity of 206 1.5±0.2 (1=sedentary; 5=heavy labour), sport and leisure physical activity intensity of 6±0.4 (1=very 207 light, 10=intense breathless), and exercise duration of 8±1 hours per week. Activities included cycling, 208 swimming, board paddling, running, walking, dance, stair climbing, gym (circuit, weight training, 209 aerobic classes), tennis, rollerblading, and martial arts. Aerobic fitness, indicated by a predicted V O 2max , 210 was categorized as 'average' for males (35±3 ml.kg -1 .min -1 ) and 'fair' for females (23±0.5 ml.kg -1 .min -1 ) 211 [15] . The average percent daily consumption of protein and CHO was slightly higher, and lower, than 212 the recommended 10-15% and 50-60%, respectively. The average percent daily consumption of <30% 213 total fat was as recommended [20] . (Table 2) 
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Of the 16 patients, 11 were taking atorvastatin, with a daily dose range of 10-80mg (1=10mg, 6=20mg, 218 3=40mg, 1=80mg). Rosuvastatin, at 10 mg/day was prescribed for 1 patient, and the remaining 4 219 E x e r c i s e M e d i c i n e patients were administering simvastatin at a dose range of 10-40mg/day (1=10mg, 1= 20mg, 2=40mg) . 220
Patients had been taking their drug for 3.5±0.6 years (range 0-10 years). There was one newly diagnosed 221 individual who had not yet commenced his statin medication. All patients ceased taking their statin for 222 3.4±0.2 weeks prior to their blood lipids analysis in Visit 2. Following this visit, patients recommenced 223 taking their medication for 26±0.7 days. A significant decrease was observed in TC, LDL-C and 224 TC/HDL-C when taking a statin, compared with in the absence of the drug (Table 3) The lack of an adverse effect on fatty acid mobilization by statins may be due to the fact that 257 their action is thought to be largely confined to the liver [22], rather than adipose tissue. Preliminary 258 research by our group on ezetimibe (Ezetrol), a non-statin whose action is confined to inhibiting 259 cholesterol absorption from the intestine [23], has also shown no effect of this drug on fat metabolism 260 during 45 minutes of moderate-intensity walking (data not published). In contrast, acipimox and fibrates, 261 significantly inhibit HSL in adipose tissue, which results in inhibiting the release of FFA during exercise 262 from this site [5, 6] . Fibrates may also reduce availability of FFA to skeletal muscle, by increasing the 263 uptake of FFA into liver with the induction of a fatty acid transporter protein [24] . 264
The findings from this study, therefore make a valuable contribution to the somewhat confusing 265 information on statins and metabolism. It has been suggested that statins, by lowering cholesterol, may 266
impairing mitochondrial function, evidenced by increased lactate production, elevated intramuscular 268 lipid stores, decreased mitochondrial activity (measured by a decrease in cytochrome C activity) and 269 lower CoQ10 levels [26, 27] . However, despite the above, it has been found that a decrease in circulating 270
CoQ10 does not result in a reduction in muscle CoQ10 [28] . Furthermore, reviews to date, have not 271 concluded that CoQ10 is required when taking statins [29, 30] . 272
Other conflicting results include reports in humans of increased resting RER with statins, 273 indicating a possible shift from fat to CHO metabolism [10, 31] . A 12-week aerobic training study 274 measured a greater increase in V O 2max in a -statin, compared with +statin group. The authors reported a 275 decline in muscle citrate enzyme activity, suggesting that statins may affect mitochondria [32] . However, 276 in contrast to the above, there are reports of simvastatin therapy in patients having no effect on RER or 277 aerobic fitness (V O 2max ) suggesting no effect on fat metabolism and aerobic capacity [30] . Additionally, 278 a 30% increase in V O 2max , indicating an increase in aerobic fitness, has been reported in patients on 279 rosuvastatin undergoing exercise training for 10 weeks [13] . 280
The conflicting results in the literature, are due to many variables, including that of studying 281 different patient groups in either the presence or absence of the drug. The current study eliminated this 282 variable, adopting a longitudinal design, with all participants required to undertake exercise with and 283 without a statin. Based on previous research in healthy volunteers [5] , the current study adopted a 3-284 week treatment period verified by assessment of plasma lipids at the end of the drug versus no drug 285 phases. The treatment period significantly lowered TC and LDL-C, confirming that it was of sufficient 286 length to obtain the desired effect of lowering circulating lipids, enabling patients to serve as suitable 287
controls. 288
To minimize disruption to patients, the current study did not adopt a cross-over design, with all 289 patients experiencing the prescreening session and the first 45-minute walk in the absence of the drug, 290 The chosen modality and intensity of exercise, with a duration of 45 minutes, was adopted as it 302 has been reported as manageable for patients and ideal for maximizing cardiovascular health benefits, 303 significantly reducing morbidity and mortality [5, 34] . Though it appears that statins do not impact fat 304 metabolism when exercising under these conditions, future studies examining different exercise 305 modalities, intensities and duration, are recommended. 306
There are many people world-wide on statins. Amongst this group are individuals who are 307 considered capable of adopting a healthier lifestyle incorporating regular exercise. This study 308 demonstrates that statins do not compromise fat metabolism during moderate-intensity aerobic exercise, 309 and therefore do not contribute to premature fatigue and an inability of the patient to complete the 310 exercise. More emphasis may therefore be placed on encouraging regular physical activity in patients to 311 maximize the benefits of concomitant therapies such as pharmaceutical intervention. Fasting blood lipids (mmol/L) in the absence(-) and presence(+) of a 
